Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Oates

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Experimental Neurology|March 10, 2005
A potent sorbitol dehydrogenase inhibitor exacerbates sympathetic autonomic neuropathy in rats with streptozotocin-induced diabetesRobert E Schmidt, Denise A Dorsey, Lucie N Beaudet, et al.
Journal of Medicinal Chemistry|January 11, 2002
Orally-effective, long-acting sorbitol dehydrogenase inhibitors: synthesis, structure-activity relationships, and in vivo evaluations of novel heterocycle-substituted piperazino-pyrimidinesMargaret Y Chu-Moyer, William E Ballinger, David A Beebe, et al.
The Journal of Biological Chemistry|May 1, 2008
Aldose reductase regulates hepatic peroxisome proliferator-activated receptor alpha phosphorylation and activity to impact lipid homeostasisLongxin Qiu, Xiaochun Wu, Jenny F L Chau, et al.
Diabetes|June 29, 2006
Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damageEric C M Ho, Karen S L Lam, Yuk Shan Chen, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 31, 2004
Central role for aldose reductase pathway in myocardial ischemic injuryYuying C Hwang, Michiyo Kaneko, Soliman Bakr, et al.
Journal of Medicinal Chemistry|May 30, 2003
A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-oneBanavara L Mylari, Sandra J Armento, David A Beebe, et al.
Journal of Medicinal Chemistry|September 30, 2005
A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congenersBanavara L Mylari, Sandra J Armento, David A Beebe, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2009
Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycleJeffrey A Pfefferkorn, Jihong Lou, Martha L Minich, et al.
Structure (London, England : 1993)|September 10, 2003
X-ray crystallographic and kinetic studies of human sorbitol dehydrogenaseThomas A Pauly, Jennifer L Ekstrom, David A Beebe, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Experimental Neurology|March 10, 2005
A potent sorbitol dehydrogenase inhibitor exacerbates sympathetic autonomic neuropathy in rats with streptozotocin-induced diabetesRobert E Schmidt, Denise A Dorsey, Lucie N Beaudet, et al.
Journal of Medicinal Chemistry|January 11, 2002
Orally-effective, long-acting sorbitol dehydrogenase inhibitors: synthesis, structure-activity relationships, and in vivo evaluations of novel heterocycle-substituted piperazino-pyrimidinesMargaret Y Chu-Moyer, William E Ballinger, David A Beebe, et al.
The Journal of Biological Chemistry|May 1, 2008
Aldose reductase regulates hepatic peroxisome proliferator-activated receptor alpha phosphorylation and activity to impact lipid homeostasisLongxin Qiu, Xiaochun Wu, Jenny F L Chau, et al.
Diabetes|June 29, 2006
Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damageEric C M Ho, Karen S L Lam, Yuk Shan Chen, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 31, 2004
Central role for aldose reductase pathway in myocardial ischemic injuryYuying C Hwang, Michiyo Kaneko, Soliman Bakr, et al.
Journal of Medicinal Chemistry|May 30, 2003
A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-oneBanavara L Mylari, Sandra J Armento, David A Beebe, et al.
Journal of Medicinal Chemistry|September 30, 2005
A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congenersBanavara L Mylari, Sandra J Armento, David A Beebe, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2009
Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycleJeffrey A Pfefferkorn, Jihong Lou, Martha L Minich, et al.
Structure (London, England : 1993)|September 10, 2003
X-ray crystallographic and kinetic studies of human sorbitol dehydrogenaseThomas A Pauly, Jennifer L Ekstrom, David A Beebe, et al.
Pageof 3